• Valemetostat: Dual EZH1/2 Inhibition in Aggressive ATL Thera

  2026-06-27

  The reference study marks the first clinical approval of Valemetostat, a dual EZH1/2 inhibitor, for adult T-cell leukemia/lymphoma (ATL), addressing epigenetic dysregulation in aggressive subtypes. This breakthrough highlights the therapeutic significance of targeting both EZH1 and EZH2 in relapsed or refractory ATL, with promising response rates and manageable safety.

• Ca2+-Dependent Autophagy and Lysosomal Alkalinization in GBM

  2026-06-26

  This study uncovers how NNC-55–0396 induces cytotoxicity in glioblastoma by triggering ER calcium-driven autophagy and disrupting lysosomal function, ultimately blocking autophagic flux. The findings clarify the multi-level regulation of stress responses in cancer cells and provide methodological insight for researchers investigating calcium signaling and autophagy interventions.

• Acacetin-Mediated MAPK1/HMOX1 Axis in IVDD: Mechanistic Insi

  2026-06-26

  This study reveals that Duhuo Jisheng decoction, via its active component acacetin, suppresses nucleus pulposus cell pyroptosis and mitigates intervertebral disc degeneration (IVDD) by modulating the MAPK1/HMOX1 axis. These findings clarify a novel link between mitophagy and pyroptosis, advancing therapeutic strategies for degenerative disc disease.

• Cell Counting Kit-8 (CCK-8): Precision Oncology Screening To

  2026-06-25

  Discover how Cell Counting Kit-8 (CCK-8) empowers precision cancer research by enabling sensitive, high-throughput cell viability and synthetic lethality screens. This in-depth article reveals advanced assay strategies and scientific insights for optimizing experimental outcomes.

• FLT3-TAZ Pathway Drives Drug Resistance in Blast Phase CML

  2026-06-25

  Shin et al. reveal that FLT3 signaling underlies resistance to BCR::ABL1 inhibitors in blast phase chronic myeloid leukemia (BP-CML), defining a new high-risk FLT3+ patient subgroup and therapeutic target. Their multi-omics approach demonstrates that FLT3-driven pathways confer TKI resistance independently of BCR::ABL1 mutations, opening new avenues for combinatorial treatment strategies.

• Cy5 NHS ester(Et): Technical Guide for Protein Labeling Work

  2026-06-24

  Cy5 NHS ester(Et) offers a high-purity, water-soluble solution for covalent labeling of primary amines in proteins and related biomolecules. It is best suited to workflows that require prompt use and compatibility with aqueous or DMSO protocols, such as immunofluorescence, flow cytometry, and fluorescence microscopy. This reagent should not be used in ethanol-based protocols or where prolonged storage of dye solutions is required.

• Protein A/G Magnetic Beads: Technical Workflows & QC

  2026-06-23

  Protein A/G Magnetic Beads (SKU K1305) provide a streamlined solution for efficient IgG antibody purification and protein-protein interaction analysis from complex samples with minimal non-specific binding. They are ideal for immunoprecipitation, co-IP, and chromatin immunoprecipitation workflows, but are not suitable for diagnostic or therapeutic applications. Use is restricted to scientific research as outlined in the product dossier.

• Substance P in Pain Transmission Research: Applied Protocols

  2026-06-23

  Substance P, a high-purity tachykinin neuropeptide, powers advanced pain transmission and inflammation studies through precise, receptor-targeted workflows. Learn how cutting-edge spectral techniques and optimized protocols boost experimental reliability and mechanistic insight.

• Bestatin (Ubenimex) in Advanced Aminopeptidase Assays

  2026-06-22

  Bestatin (Ubenimex) enables precise, high-specificity inhibition of aminopeptidases in multidrug resistance and cancer research. This guide delivers stepwise protocols, troubleshooting strategies, and actionable insights from cutting-edge studies to empower reproducible, data-rich workflows.

• 3-Deazaadenosine Hydrochloride in Hepatic Fibrosis Research

  2026-06-22

  3-Deazaadenosine hydrochloride empowers targeted methylation pathway modulation in hepatic stellate cell and fibrosis studies. APExBIO’s high-purity S-adenosylhomocysteine hydrolase inhibitor streamlines experimental workflows and troubleshooting for advanced inflammation, proliferation, and m6A-related research.

• Panobinostat (LBH589): Redefining Macrophage Polarization an

  2026-06-21

  Explore how Panobinostat (LBH589) advances epigenetic regulation research by modulating macrophage polarization and extracellular matrix remodeling. This article uncovers unique mechanistic insights and practical assay implications for cancer and myopia research.

• Aminopeptidase Inhibitors in Next-Generation Cancer Therapy

  2026-06-20

  This review critically examines the positioning of aminopeptidase inhibitors, such as Bestatin (Ubenimex), in the context of emerging cancer therapies. By detailing the mechanistic roles of key aminopeptidases and recent innovations in inhibitor development, the study underscores their promise for overcoming drug resistance and optimizing combination regimens.

• CARMIL MB Domain: Regulation of Capping Protein & Actin Asse

  2026-06-19

  The reference study uncovers the pivotal role of the CARMIL membrane-binding (MB) domain in targeting and activating actin capping protein (CP) at cellular membranes. By dissecting the MB domain’s mechanism in CP localization, activation, and release, the work advances our understanding of actin filament regulation and offers new strategies for cytoskeletal research.

• AngII Drives M1 Macrophage Polarization via Cx43/NF-κB Pathw

  2026-06-19

  This study uncovers how angiotensin II (AngII) induces RAW264.7 macrophages to polarize toward a pro-inflammatory M1 phenotype through the connexin 43 (Cx43)/NF-κB pathway. The findings clarify the molecular mechanisms of macrophage activation and highlight Cx43 hemichannel inhibition as a promising experimental strategy for dissecting immune signaling in inflammatory disease models.

• TH287 MTH1 Inhibitor Enhances Radiosensitivity in CRPC Cells

  2026-06-18

  The reference study demonstrates that the MTH1 inhibitor TH287 significantly enhances the sensitivity of castration-resistant prostate cancer (CRPC) cells to ionizing radiation by promoting DNA damage, apoptosis, and cell cycle arrest. These findings establish an optimized timing for combination therapy and provide mechanistic and protocol guidance for radiosensitization strategies in advanced prostate cancer research.

16905 records 2/1127 page Previous Next 12345 下5页 Last page